{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:26:49Z","timestamp":1790468809058,"version":"4.1.0"},"reference-count":27,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2013,2,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Inotuzumab ozogamicin (INO) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to calicheamicin, a potent cytotoxic agent. We performed a phase I\/II study to determine the maximum-tolerated dose (MTD), safety, efficacy, and pharmacokinetics of INO plus rituximab (R-INO) for treatment of relapsed\/refractory CD20\n                      <jats:sup>+<\/jats:sup>\n                      \/CD22\n                      <jats:sup>+<\/jats:sup>\n                      B-cell non-Hodgkin lymphoma (NHL).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>A dose-escalation phase to determine the MTD of R-INO was followed by an expanded cohort to further evaluate the efficacy and safety at the MTD. Patients with relapsed follicular lymphoma (FL), relapsed diffuse large B-cell lymphoma (DLBCL), or refractory aggressive NHL received R-INO every 4 weeks for up to eight cycles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In all, 118 patients received one or more cycles of R-INO (median, four cycles). Most common grade 3 to 4 adverse events were thrombocytopenia (31%) and neutropenia (22%). Common low-grade toxicities included hyperbilirubinemia (25%) and increased AST (36%). The MTD of INO in combination with rituximab (375 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) was confirmed to be the same as that for single-agent INO (1.8 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ). Treatment at the MTD yielded objective response rates of 87%, 74%, and 20% for relapsed FL (n = 39), relapsed DLBCL (n = 42), and refractory aggressive NHL (n = 30), respectively. The 2-year progression-free survival (PFS) rate was 68% (median, not reached) for FL and 42% (median, 17.1 months) for relapsed DLBCL.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      R-INO demonstrated high response rates and long PFS in patients with relapsed FL or DLBCL. This and the manageable toxicity profile suggest that R-INO may be a promising option for CD20\n                      <jats:sup>+<\/jats:sup>\n                      \/CD22\n                      <jats:sup>+<\/jats:sup>\n                      B-cell NHL.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2012.42.7211","type":"journal-article","created":{"date-parts":[[2013,1,8]],"date-time":"2013-01-08T17:42:27Z","timestamp":1357666947000},"page":"573-583","source":"Crossref","is-referenced-by-count":145,"title":["Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I\/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab"],"prefix":"10.1200","volume":"31","author":[{"given":"Luis","family":"Fayad","sequence":"first","affiliation":[{"name":"Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritz","family":"Offner","sequence":"additional","affiliation":[{"name":"Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell R.","family":"Smith","sequence":"additional","affiliation":[{"name":"Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Verhoef","sequence":"additional","affiliation":[{"name":"Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Johnson","sequence":"additional","affiliation":[{"name":"Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ama","family":"Rohatiner","sequence":"additional","affiliation":[{"name":"Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Advani","sequence":"additional","affiliation":[{"name":"Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Foran","sequence":"additional","affiliation":[{"name":"Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Hess","sequence":"additional","affiliation":[{"name":"Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Coiffier","sequence":"additional","affiliation":[{"name":"Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron","family":"Czuczman","sequence":"additional","affiliation":[{"name":"Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Gin\u00e9","sequence":"additional","affiliation":[{"name":"Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Durrant","sequence":"additional","affiliation":[{"name":"Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Kneissl","sequence":"additional","affiliation":[{"name":"Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth T.","family":"Luu","sequence":"additional","affiliation":[{"name":"Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Y.","family":"Hua","sequence":"additional","affiliation":[{"name":"Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Boni","sequence":"additional","affiliation":[{"name":"Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Vandendries","sequence":"additional","affiliation":[{"name":"Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam H.","family":"Dang","sequence":"additional","affiliation":[{"name":"Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH;..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","unstructured":"Lymphoma, non-Hodgkin type American Cancer Society http:\/\/www.cancer.org\/cancer\/non-hodgkinlymphoma\/detailedguide\/non-hodgkin-lymphoma-types-of-non-hodgkin-lymphoma"},{"key":"B2","doi-asserted-by":"crossref","first-page":"350a","DOI":"10.1182\/blood-2001-12-0276","volume":"100","author":"Cesano A","year":"2002","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/1040-8428(91)90029-C"},{"key":"B4","first-page":"3336","volume":"53","author":"Hinman LM","year":"1993","journal-title":"Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1021\/ja00029a030"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2174\/1381612003398564"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/science.3240341"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2466"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1021\/bc010021y"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.1900"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1905"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1134"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"B17","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner R","year":"2004","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50024"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh093"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021113"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0001"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13440"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00996.x"},{"key":"B27","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(08)70078-0","volume":"9","author":"Pfreundschuh M","year":"2008","journal-title":"Lancet Oncol"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2012.42.7211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T19:03:30Z","timestamp":1653505410000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2012.42.7211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,10]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,2,10]]}},"alternative-id":["10.1200\/JCO.2012.42.7211"],"URL":"https:\/\/doi.org\/10.1200\/jco.2012.42.7211","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717976077.793470431","asserted-by":"object"}]},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,10]]}}}